1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Classification 31
3.3 Symptoms 35
3.4 Course 38
3.5 Prognosis 39
4 Epidemiology 41
4.1 Disease Background 41
4.2 Risk Factors and Comorbidities 42
4.3 Global Trends 45
4.3.1 US 46
4.3.2 5EU 46
4.3.3 Japan 47
4.4 Forecast Methodology 49
4.4.1 Sources Used 50
4.4.2 Forecast Assumptions and Methods 51
4.4.3 Sources Not Used 57
4.5 Epidemiological Forecast for Schizophrenia (2015-2025) 58
4.5.1 12-Month Diagnosed Prevalent Cases of Schizophrenia 58
4.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 60
4.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 61
4.5.4 Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia 63
4.6 Discussion 64
4.6.1 Epidemiological Forecast Insight 64
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66
5 Disease Management 67
5.1 Diagnosis Overview 67
5.1.1 Clinical Evaluation 67
5.2 Treatment Overview 69
5.2.1 Treatment Initiation 69
5.2.2 Maintenance Treatment 71
5.2.3 Treatment of Breakthrough Episodes 72
5.2.4 Long-Acting Injectables 73
5.2.5 Treatment-Resistance 75
5.2.6 Acute Agitation 79
5.2.7 Adjunctive Psychotherapy 80
5.3 Treatment Guidelines and Leading Prescribed Drugs 81
5.4 US 83
5.5 5EU 86
5.6 Japan 89
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles – Atypical Antipsychotics 96
6.2.1 Abilify (aripiprazole) 96
6.2.2 Aristada (aripiprazole lauroxil) 109
6.2.3 Clozapine (widely genericized) 116
6.2.4 Fanapt (iloperidone) 123
6.2.5 Geodon (ziprasidone) 130
6.2.6 Invega (paliperidone) 135
6.2.7 Latuda (lurasidone) 149
6.2.8 Lonasen (blonanserin) 156
6.2.9 Rexulti (brexpiprazole) 161
6.2.10 Risperdal (risperidone) 167
6.2.11 Saphris (asenapine) 180
6.2.12 Seroquel (quetiapine) 187
6.2.13 Vraylar (cariprazine) 200
6.2.14 Zyprexa (olanzapine) 207
6.3 Product Profiles – Typical Antipsychotics 220
6.3.1 Typical Antipsychotics 220
6.3.2 Adasuve (Staccato loxapine) 224
6.4 Other Therapeutic Classes 230
7 Unmet Needs and Opportunities 231
7.1 Overview 231
7.2 Development of Cognitive-Enhancing Drugs 233
7.2.1 Unmet Need 233
7.2.2 Gap Analysis 234
7.2.3 Opportunity 234
7.3 Development of Drugs to Treat Negative Symptoms 234
7.3.1 Unmet Need 234
7.3.2 Gap Analysis 235
7.3.3 Opportunity 236
7.4 Improved Treatment Options for Treatment-Resistant Patients 236
7.4.1 Unmet Need 236
7.4.2 Gap Analysis 237
7.4.3 Opportunity 237
7.5 Development of Drugs with Enhanced Safety Profiles 238
7.5.1 Unmet Need 238
7.5.2 Gap Analysis 239
7.5.3 Opportunity 239
7.6 Development of Drugs to Increase Compliance 239
7.6.1 Unmet Need 239
7.6.2 Gap Analysis 241
7.6.3 Opportunity 241
8 Pipeline Assessment 242
8.1 Overview 242
8.1.1 Clinical Trials by Class of Therapy 242
8.2 Promising Drugs in Clinical Development 243
8.2.1 ALKS-3831 245
8.2.2 ITI-007 253
8.2.3 Lu AF35700 262
8.2.4 MIN-101 265
8.2.5 Risperidone implant 274
8.2.6 Risperidone ISM 281
8.2.7 RBP-7000 286
8.2.8 AVN-211 295
8.2.9 NaBen 303
8.3 Other Drugs in Development 311
9 Current and Future Players 314
9.1 Overview 314
9.2 Trends in Corporate Strategy 317
9.3 Company Profiles 319
9.3.1 Alkermes 319
9.3.2 Dainippon Sumitomo 321
9.3.3 Eli Lilly 324
9.3.4 Intra-Cellular Therapies 326
9.3.5 Janssen 328
9.3.6 Lundbeck 331
9.3.7 Minerva Neurosciences 334
9.3.8 Otsuka 336
10 Market Outlook 340
10.1 Global Markets 340
10.1.1 Forecast 340
10.1.2 Drivers and Barriers – Global Issues 344
10.2 US 344
10.2.1 Forecast 344
10.2.2 Key Events 348
10.2.3 Drivers and Barriers 349
10.3 5EU 349
10.3.1 Forecast 349
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Japan 353
10.4.1 Forecast 353
10.4.2 Key Events 356
10.4.3 Drivers and Barriers 357
11 Appendix 358
11.1 Bibliography 358
11.2 Abbreviations 400
11.3 Methodology 406
11.4 Forecasting Methodology 406
11.4.1 Diagnosed Schizophrenia Patients 406
11.4.2 Percent Drug-Treated Patients 407
11.4.3 Launch and Patent Expiry Dates 407
11.4.4 General Pricing Assumptions 408
11.4.5 Individual Drug Assumptions 409
11.4.6 Generic Erosion 424
11.4.7 Pricing of Pipeline Agents 424
11.5 Primary Research – KOLs Interviewed for this Report 426
11.6 Primary Research – Prescriber Survey 428
11.7 About the Authors 429
11.7.1 Analyst 429
11.7.2 Therapy Area Director 430
11.7.3 Epidemiologist 430
11.7.4 Managing Epidemiologist 431
11.7.5 Global Director of Therapy Analysis and Epidemiology 431
11.8 About GlobalData 432
11.9 Disclaimer 432